[CH3:1][N:2]([CH3:29])[C:3]([C:5]1[NH:27][C:8]2[CH2:9][C@@:10]3([C:19]4[CH:24]=[CH:23][CH:22]=[C:21]([O:25]C)[CH:20]=4)[C@H:15]([CH2:16][C:7]=2[C:6]=1[CH3:28])[CH2:14][N:13]([CH2:17][CH3:18])[CH2:12][CH2:11]3)=[O:4].B(Br)(Br)Br.[ClH:34].CCOCC>CO>[ClH:34].[CH3:29][N:2]([CH3:1])[C:3]([C:5]1[NH:27][C:8]2[CH2:9][C@@:10]3([C:19]4[CH:24]=[CH:23][CH:22]=[C:21]([OH:25])[CH:20]=4)[C@H:15]([CH2:16][C:7]=2[C:6]=1[CH3:28])[CH2:14][N:13]([CH2:17][CH3:18])[CH2:12][CH2:11]3)=[O:4]0.5 g (1.25 mmol) of (±)trans-2-dimethylaminocarbonyl-6-ethyl-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline were treated with 0.725 ml (7.5 mmol) of boron tribromide as described in example 2. The etude product was dissolved in MeOH and the solution brought to acidic pH with HCl/Et2O. The solvent was evaporated in vacuo and the solid crystallized from EtOH, yielding 0.15 g of the title compound. M.p.=305° C. dec.